The intervention of metformin as add-on to insulin on LADA patients: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016049

Enrollment

Unknown

Registered

2018-05-08

Start date

2014-01-01

Completion date

Unknown

Last updated

2018-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent autoimmune diabetes of adults (LADA)

Interventions

Metformin+Insulin:Patients are prescribed with 500-850mg metformin twice daily with insulin

Insulin alone:Patients will continue insulin therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) diabetes diagnosed according to the report of the World Health Organization in 1999 at age = 30 years; 2) positive for GADA; 3) insulin independent within the first 6 months after the diagnosis of diabetes; 4) Informed consent obtained

Exclusion criteria

Exclusion criteria: 1) history of any malignancy or other severe diseases; 2) female patients who are pregnant or breastfeeding before or during the three-year follow-up; 3) poor compliance or refusal to participate.

Design outcomes

Primary

Measure	Time frame
HbA1c;C-peptide;	—

Secondary

Measure	Time frame
GADA;lipid profile;body mass index (BMI);waist-hip ratio (WHR);	—

Countries

China

Contacts

Public ContactZhiguang Zhou

The Second Xiangya Hospital of Central South University

zhouzg@hotmail.com+86 731 85292154

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026